Evidence map›Paper›PMID 38767352›Full record

ArticleJournal of virology2024

An mRNA-LNP-based Lassa virus vaccine induces protective immunity in mice.

Mei Hashizume, Ayako Takashima, Masaharu Iwasaki

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of virology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Robust polyfunctional CD8The Journal of general virology · 2025
    Article
  5. Review
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Mei HashizumeLaboratory of Emerging Viral Diseases, International Research Center for Infectious Diseases, Research Institute for Microbial Diseases, Osaka University, Suita, Osaka, Japan.
Ayako TakashimaLaboratory of Emerging Viral Diseases, International Research Center for Infectious Diseases, Research Institute for Microbial Diseases, Osaka University, Suita, Osaka, Japan.
Masaharu IwasakiLaboratory of Emerging Viral Diseases, International Research Center for Infectious Diseases, Research Institute for Microbial Diseases, Osaka University, Suita, Osaka, Japan.ORCID 0000-0002-7117-461X

Funding

Japan Agency for Medical Research and Development (AMED) JP22fm0208101, JP23fm0208101, JP22ym0126815, JP23ym0126815, JP233fa627002
6 · The paper itself

Abstract

The mammarenavirus Lassa virus (LASV) causes the life-threatening hemorrhagic fever disease, Lassa fever. The lack of licensed medical countermeasures against LASV underscores the urgent need for the development of novel LASV vaccines, which has been hampered by the requirement for a biosafety level 4 facility to handle live LASV. Here, we investigated the efficacy of mRNA-lipid nanoparticle (mRNA-LNP)-based vaccines expressing the LASV glycoprotein precursor (LASgpc) or nucleoprotein (LCMnp) of the prototypic mammarenavirus, lymphocytic choriomeningitis virus (LCMV), in mice. Two doses of LASgpc- or LCMnp-mRNA-LNP administered intravenously (i.v.) protected C57BL/6 mice from a lethal challenge with a recombinant (r) LCMV expressing a modified LASgpc (rLCMV/LASgpc

Indexed as

Lassa FeverLassa virusLymphocytic choriomeningitis virusNanoparticlesViral VaccinesAnimalsAntibodies, NeutralizingAntibodies, ViralDisease Models, AnimalFemaleGlycoproteinsLiposomesMiceMice, Inbred C57BLNucleoproteinsRNA, MessengerAntibodies, NeutralizingAntibodies, ViralGlycoproteinsLipid NanoparticlesLiposomesNucleoproteinsRNA, MessengerViral Vaccineshemorrhagic feverLassa viruslipid nanoparticlelymphocytic choriomeningitis virusmammarenavirusmRNAvaccines

Identifiers

PMID38767352
PMCPMC11237644

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.